HIGHLIGHTS
- What: Prior to commencing treatment with biological agents such as Certolizumab Pegol, it is essential to engage in thorough discussions with the patient, providing comprehensive orientation regarding the risks of infections and other potential adverse events.
- Who: Certolizumab Pegol et al. from the Danish Hospital for Rheumatic Diseases, Snderborg, Denmark University of Southern Denmark, Department of Regional Health Research, Odense, Denmark have published the paper: Volume 09; Issue 06 Ann Case Rep, an open access journal ISSN: 2574-7754, in the Journal: (JOURNAL) of February/12,/2019
SUMMARY
Infections pose a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.